vivo has had quite some good responses.
Just one more thing to add.
T cell therapy sales are in the $10's billions a year. In four years it is expected to be over $100 billion and rising. Deals in the space are often multi-billion deals, even for early stage drugs.
imu's technologies have the ability to wipe out T cell therapies for good, if the expected better safety profile and efficacy comes through. This means that imu is a viable partner/take over target even now. Because the potential (and I believe it's a very realistic potential) and threat is huge and relevant to now.
This is why imu is worth a hell of a lot more than its current market cap, despite what the upturned egg-plant on the candle-stick with head and shoulders on the chart might say!
;-)
no offense to chartists intended.
Add to My Watchlist
What is My Watchlist?
